Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
9.50
-0.27 (-2.76%)
At close: Aug 5, 2025, 4:00 PM
9.50
0.00 (0.00%)
After-hours: Aug 5, 2025, 7:00 PM EDT
Evolent Health Revenue
Evolent Health had revenue of $483.65M in the quarter ending March 31, 2025, a decrease of -24.39%. This brings the company's revenue in the last twelve months to $2.40B, up 10.24% year-over-year. In the year 2024, Evolent Health had annual revenue of $2.55B with 30.09% growth.
Revenue (ttm)
$2.40B
Revenue Growth
+10.24%
P/S Ratio
0.46
Revenue / Employee
$533,053
Employees
4,500
Market Cap
1.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.55B | 590.85M | 30.09% |
Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EVH News
- 22 days ago - Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - PRNewsWire
- 27 days ago - Evolent announces key appointments to leadership team - PRNewsWire
- 6 weeks ago - Evolent reiterates Q2 and full year guidance for Adjusted EBITDA - PRNewsWire
- 3 months ago - Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Evolent Announces First Quarter 2025 Results - PRNewsWire
- 3 months ago - Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors - PRNewsWire
- 4 months ago - Evolent program achieves 20% reduction in use of low-value oncology regimens - PRNewsWire
- 4 months ago - Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 - PRNewsWire